Predictors of amputation and survival following lower extremity revascularization in hemodialysis patients  by Jaar, Bernard G. et al.
Kidney International, Vol. 65 (2004), pp. 613–620
Predictors of amputation and survival following lower extremity
revascularization in hemodialysis patients
BERNARD G. JAAR, BRAD C. ASTOR, JEFFREY S. BERNS, and NEIL R. POWE
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Welch Center for Prevention,
Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland; Department of Epidemiology,
Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; Department of Health Policy and
Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; and the Renal, Electrolyte,
and Hypertension Division, University of Pennsylvania, Philadelphia, Pennsylvania
Predictors of amputation and survival following lower extremity
revascularization in hemodialysis patients.
Background. Peripheral vascular disease (PVD) has become
increasingly common in end-stage renal disease (ESRD) pa-
tients, leading to an increase in the rate of revascularization
and amputation. We studied the prognosis of ESRD patients
undergoing their first revascularization procedure.
Methods. We conducted a longitudinal cohort study of
hemodialysis patients enrolled in special studies of the United
States Renal Data System. Cox proportional hazards analysis
was used to assess the independent effect of type of initial revas-
cularization procedure on lower extremity amputation and
all-cause, cardiac, and infectious mortality over 3 years, after
adjustment for sociodemographic, clinical, and biologic base-
line characteristics.
Results. Eight hundred patients underwent an initial revas-
cularization procedure by surgical bypass or angioplasty. The
overall incidence of subsequent amputation was 16.3/100
person-years, 22.6 for bypass, and 5.7 for angioplasty. After ad-
justment for patient characteristics, the risk of amputation was
higher for bypass versus angioplasty [relative hazard (RH) 4.00;
95% CI 2.46 to 6.57], for black versus white patients (RH 1.49;
95% CI 1.04 to 2.15), for uninsured or patients on Medicaid ver-
sus patients with private insurance or on Medicare (RH 1.65;
95% CI 1.12 to 2.72), and for patients with diabetes versus no di-
abetes (RH 2.51; 95% CI 1.67 to 3.76). Compared with patients
who underwent angioplasty, the risk of all-cause (RH 1.37; 95%
CI 1.10 to 1.70), cardiac (RH 1.50; 95% CI 1.08 to 2.09), and
infectious (RH 2.17; 95% CI 1.10 to 4.29) mortality was greater
among patients who underwent bypass.
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Conclusion. Risk of amputation following revascularization
procedures was positively associated with type of procedure,
black race, uninsurance/Medicaid, and diabetes status. Risk of
death was also higher following bypass. While this might reflect
underlying severity of disease, patient education, screening, and
optimal care of lower extremities should be emphasized to de-
tect PVD at an early stage of the disease process.
End-stage renal disease (ESRD) represents a vas-
culopathic state [1] with atherosclerotic cardiovascular
disease remaining the major contributor to the high mor-
bidity and mortality observed in the ESRD population,
accounting for 36% of deaths (total annual death rate of
182.4 per 1000 patient-years) [2]. With the aging popula-
tion and the increasing prevalence of diabetes mellitus,
lower extremity peripheral vascular disease (PVD) has
become increasingly common in ESRD patients, leading
to an increase in the need for procedures for revascular-
ization and amputation in this population [2]. The most
striking increase in PVD-related procedures occurred in
patients undergoing their first year of dialysis, with a 51%
increase in the rate of PVD-related procedures (major
amputation and peripheral revascularization), from 84
events per 1000 patients in 1991 to 128 events per 1000
patients in 1998 [2]. Furthermore, nontraumatic lower ex-
tremity amputation is more prevalent among the Medi-
care ESRD population than in the general population at
large [3].
Methods to achieve a reduction in amputation rates
among patients with PVD are available today. Arterial
reperfusion with the use of bypass grafts to pedal vessels
represents an important advance in limb salvage proce-
dures in the general population [4]. Despite significant
advances in these procedures, the role of vascular re-
construction for severe PVD in the high-risk group of
patients with ESRD has remained controversial [5–9].
Uncontrolled case series of lower extremity surgical
revascularization for PVD in patients with ESRD have
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in general shown poor results compared to the general
population [5, 6, 10] and this has led some authors to
consider primary amputation for the treatment of severe
lower extremity ischemia [5, 6]. Furthermore, the role of
angioplasty in the treatment of PVD has not been studied
in patients with ESRD.
The purpose of the study was to describe outcomes of
primary lower extremity revascularization for PVD in a
representative sample of the United States hemodialysis
population.
METHODS
Research design and patient eligibility
We performed a longitudinal cohort study of the inci-
dence and risk factors for lower extremity amputations
following revascularization for PVD in hemodialysis
patients. The study population was drawn from Waves
I, III, and IV of the Dialysis Mortality and Morbidity
Study (DMMS) of the United States Renal Data System
(USRDS). Waves I, III, and IV were all cross-sectional
studies of a nationally representative random sample of
patients who were undergoing hemodialysis on Decem-
ber 31, 1993 and selected from 550 dialysis units [11]. To
be eligible for this analysis, patients had to be at least
18 years old and not undergone a peripheral revascular-
ization procedure or lower extremity amputation prior to
starting chronic hemodialysis.
Data collection
Baseline data were obtained from the DMMS Stan-
dard Analysis file from the USRDS [11]. Data were
abstracted from patient medical records by dialysis fa-
cility personnel and completed in August 1995 for Wave
I and during 1997 for Waves III and IV. Data included
information on patient demographics, comorbid condi-
tions present in the last 10 years, psychosocial factors,
laboratory values, and dialysis treatments. Race was cat-
egorized as white or black. Because few patients under-
going lower extremity revascularization reported other
races (N = 31), these patients were excluded from anal-
ysis. Insurance was categorized as private or Medicare
versus Medicaid or no insurance. Smoking was defined
as ever smoking versus never smoking. A participant was
classified as diabetic if a prior diagnosis of diabetes was
recorded or the participant was on insulin. Patients were
considered to have a history of cardiovascular disease
if they had undergone coronary angioplasty or coronary
artery bypass graft surgery or had been diagnosed with:
angina, myocardial infarction, or coronary artery disease.
Serum albumin was calculated as the average of up to
four measurements recorded monthly from September
to December 1993. Other laboratory values were those
recorded closest to December 31, 1993, from a period of
up to 3 months before to 1 month after December 31,
1993.
Follow-up data for up to 3 years were obtained from de-
tailed USRDS files that contained information on deaths
and Medicare inpatient claims through December 31,
1996. Procedure codes from the International Classifi-
cation of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) were used to identify lower extremity revas-
cularization by surgical bypass (39.25, 39.29) or angio-
plasty (39.50, 39.90) and lower extremity amputation
below the knee (BKA) (84.15) or above the knee (AKA)
(84.17) [12].
Statistical analysis
The chi-square test and t test were used to compare
differences in characteristics between patients with and
without revascularization and by PVD revascularization
procedure. Follow-up time was calculated starting at the
date of the first lower extremity revascularization proce-
dure recorded until December 31, 1996, for a maximum
of 3 years. Patients were censored at the time of death,
renal transplantation, switch to peritoneal dialysis, or loss
to follow-up. Time to subsequent infectious, cardiovascu-
lar and all-cause death was analyzed using Kaplan-Meier
estimates [13] for the entire cohort and after stratifica-
tion by type of initial revascularization procedure. Cox
proportional hazards models [14] were used to examine
the independent effect of type of initial revascularization
procedure on lower extremity amputation and death after
adjustment for sociodemographic (age, gender, race, ed-
ucation, and type of insurance at initiation of hemodial-
ysis), clinical (presence of diabetes mellitus, history of
smoking, coronary artery disease, cerebrovascular dis-
ease, and time on dialysis) and biologic [hematocrit,
serum albumin, calcium-phosphate product and intact
parathyroid hormone (PTH)] characteristics at baseline.
We tested for the proportionality assumption and where
it was not proportional we stratified the survival curves
at the point of separation. We created dummy variables
for participants missing data on smoking status (12%),
education (18%), serum albumin (9%), hematocrit (8%),
calcium x phosphate product (9%), or intact PTH (36%).
Statistical analyses were performed using SAS (SAS In-
stitute, Cary, NC, USA) and Stata (StataCorp, College
Station, TX, USA).
RESULTS
Patient characteristics
Of the 13,942 eligible patients included in Waves I,
III, and IV of the DMMS, 800 had a first lower extrem-
ity revascularization either by surgical bypass or angio-
plasty after starting chronic hemodialysis treatment. The
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Table 1. Characteristics of hemodialysis patients with and without lower
extremity revascularization for peripheral vascular disease (PVD)
No
revascularization Revascularization
Characteristics (N = 13,142) (N = 800) P value
Age years (mean ± SD) 60.0 ± 15.5 63.1 ± 13.1 <0.0001
Male gender % 52.0 50.6 0.45
White race % 55.4 58.5 0.08
High school graduate % 56.5 52.9 0.07
Type of Insurance
Private/Medicare 76.4 80.4 0.02
Medicaid/None 23.7 19.6
History of smoking % 32.0 37.2 0.002
Dialysis vintage years 3.2 ± 3.6 2.7 ± 2.8 <0.001
Coronary artery disease % 57.8 54.8 0.20
Diabetes mellitus % 42.4 53.9 <0.001
Prior transplantation % 7.3 4.3 0.001
Serum albumin g/dL 3.73 ± 0.43 3.75 ± 0.39 0.11
(mean ± SD)
Hematocrit % 30.5 + 4.7 30.8 ± 4.3 0.08
(mean ± SD)
Ca x P product mg2/dL2 55.4 ± 21.9 55.4 ± 18.3 0.99
(mean ± SD)
Serum intact parathyroid 417.9 ± 1317.1 346.0 ± 845.0 0.22
hormone pg/mL
(mean ± SD)
characteristics of these patients were compared with the
13,142 patients who did not have a primary revascular-
ization or a primary amputation (Table 1). Patients un-
dergoing lower extremity revascularization were 3 years
older than their counter parts (63.1 versus 60.0 years, re-
spectively; P < 0.0001) and were more likely to have a
history of smoking (37.2% versus 32.0%, respectively;
P = 0.002), and diabetes mellitus (53.9% versus 42.4%,
respectively; P < 0.001). Patients undergoing lower ex-
tremity revascularization were less likely to have received
a kidney transplant prior to the start of the study (4.3%
versus 7.3%; P = 0.001) than were patients who did not
undergo revascularization. These groups did not differ in
terms of gender, race, history of coronary artery disease,
education, or any of the other biological characteristics
described above.
Five hundred eight (63.5%) patients underwent a
revascularization by surgical bypass, while 292 (36.5%)
patients underwent a revascularization by angioplasty
(Table 2). Surgical bypass patients were older (P < 0.001),
and more likely to be male (P = 0.02), white (P = 0.008),
have a history of smoking (P = 0.007), coronary artery
disease (P < 0.001), diabetes mellitus (P < 0.001), and
lower serum albumin concentration (P = 0.05).
Following a primary revascularization by surgical
bypass, 186 (36.6%) patients had subsequent PVD-
related procedures, including 86 repeat bypasses, 25 an-
gioplasty procedures, and 120 amputations. Following a
primary revascularization by angioplasty, 54 (18.5%) pa-
tients had subsequent PVD-related procedures, includ-
ing 33 repeat angioplasty procedures, 12 bypasses, and 18
amputations.
Table 2. Characteristics of 800 hemodialysis patients undergoing
lower extremity revascularization by bypass or angioplasty for
peripheral vascular disease (PVD)
Bypass surgery Angioplasty
Characteristics (N = 508) (N = 292) P value
Age years (mean ± SD) 64.4 ± 12.0 61.2 ± 14.7 0.001
Male gender % 53.7 45.2 0.02
White race % 67.3 52.4 0.008
High school graduate % 55.5 49.6 0.19
Type of Insurance
Private/Medicare 82.7 76.6 0.12
Medicaid/None 17.3 23.4
History of smoking % 41.1 31.5 0.007
Coronary artery disease % 60.8 44.2 <0.001
Diabetes mellitus % 59.3 44.2 <0.001
Prior transplantation % 3.5 5.8 0.13
Serum albumin g/dL 3.74 + 0.40 3.80 ± 0.36 0.05
(mean ± SD)
Hematocrit % 30.9 + 4.2 30.5 ± 4.4 0.18
(mean ± SD)
Ca x P product mg2/dL2 55.8 ± 18.8 54.7 ± 17.4 0.44
(mean ± SD)
Serum intact parathyroid 367.5 ± 1020.2 309.0 ± 390.8 0.45
hormone pg/mL
(mean ± SD)
Timing and incidence of lower extremity amputation
Among the 508 patients who underwent a primary
revascularization by bypass, 120 of them had a subsequent
amputation, with a median time of 86 days between the
two procedures (ranging from 8 days to 196 days). Among
the 292 patients who underwent a primary revasculariza-
tion by angioplasty, only 18 of them had a subsequent
amputation, with a median time of 106 days between the
two procedures (ranging from 13 days to 811 days).
Follow-up through 1996 identified 138 patients un-
dergoing amputation following a primary revasculariza-
tion procedure for PVD. The total time at risk was 847
person-years. The overall incidence rate of subsequent
amputation following a first revascularization procedure
was 16.3/100 person-years (Table 3), 22.6 for bypass, and
5.7 for angioplasty. The rate was higher among diabetic
patients compared to nondiabetic patients, and higher
among patients with a history of coronary artery disease
compared to patients with no history of coronary artery
disease. The rate of amputation was also much higher
among patients with no insurance or Medicaid compared
to patients with private insurance or Medicare, and higher
among patients with serum albumin less than 3.5 g/dL
compared to patients with serum albumin equal or more
than 3.5 g/dL.
Risk of lower extremity amputation
Lower extremity revascularization by surgical bypass
was associated with a fourfold increase in the risk for a
lower extremity amputation in multivariate proportional
hazards analysis when compared to revascularization by
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Table 3. Incidence rate of amputation among 800 hemodialysis
patients undergoing lower extremity revascularization by bypass or
angioplasty for peripheral vascular disease (PVD)
Incidence
rate
(/100 patient-
Characteristics years) P value
Overall 16.3
First procedure Bypass 22.6 <0.001
Angioplasty 5.7
Age <65 16.3 0.98
≥ 65 16.3
Gender Male 18.7 0.11
Female 14.2
Race White 15.3 0.44
Black 17.4
Education ≥High school 15.4 0.73
<High school 16.5
Type of insurance Private or Medicare 14.6 0.04
Medicaid or none 23.1
History of smoking + 17.5 0.49
– 15.5
Coronary artery disease + 20.6 0.003
– 12.2
Diabetes mellitus + 23.9 <0.001
– 8.5
Prior transplantation + 8.9 0.20
– 16.7
Serum albumin g/dL <3.5 25.9 0.01
≥ 3.5 15.0
angioplasty [relative hazard (RH) 4.00; 95% CI 2.46 to
6.57] after adjustment for age, gender, race, education,
insurance, history of smoking, presence of diabetes melli-
tus, coronary artery disease, cerebrovascular disease, time
on dialysis prior to study start date, hematocrit, serum
albumin, serum intact PTH, and serum calcium x phos-
phate product (Table 4). Patients with no insurance or on
Medicaid had a 1.7-fold increase, diabetic patients had a
2.5-fold increase in the risk, and black patients had a 1.5-
fold increase in the risk of lower extremity amputation
following a revascularization procedure after adjustment.
There was no association with the risk of lower extremity
amputation following revascularization by age, history of
smoking, presence of coronary artery disease, and time
on hemodialysis. There was a 1.5-fold increase in the risk
of lower extremity amputation following revasculariza-
tion in patients with serum albumin less than 3.5 mg/dL
but this was not statistically significant.
Survival
The 30-day all-cause mortality following revasculariza-
tion was 12.6% for patients who underwent a surgical by-
pass and 7.5% for patients who underwent an angioplasty.
Figure 1 display the cumulative mortality for all-cause,
cardiac, and infectious death, respectively. The 2-year all-
cause mortality was 57% overall, 63% after bypass, and
43% after angioplasty. The 2-year cardiovascular mortal-
ity was 32% overall, 38% after bypass, and 20% after
Table 4. Relative hazard of amputation among 800 hemodialysis
patients undergoing lower extremity revascularization (all
procedures)
Unadjusted Adjusted
relative relative
Characteristics hazard 95% CI hazard 95% CI
Bypass vs. angioplasty 4.43a 2.70–7.28 4.00a 2.46–6.57
Age (per 10 years) 1.11 0.98–1.26 1.12 0.95–1.29
Gender: male vs. female 1.27 0.91–1.78 1.37 0.95–1.98
Race: black vs. white 1.20 0.86–1.67 1.49a 1.04–2.15
High school graduate vs.
no high school diploma
0.93 0.65–1.35 1.12 0.75–1.67
No insurance or
Medicaid vs. private or
Medicare
1.48 0.96–2.28 1.65a 1.12–2.72
History of smoking
vs. none
1.09 0.77–1.53 0.98 0.68–1.42
Coronary artery disease
vs. none
1.50a 1.06–2.11 1.04 0.71–1.53
Diabetes mellitus
vs. none
2.67a 1.83–3.91 2.51a 1.67–3.76
Prior transplantation
vs. none
0.57 0.21–1.54 0.81 0.27–2.45
Time on dialysis
(per year)
0.99 0.93–1.06 1.03 0.96–1.10
Serum albumin
(<3.5 vs. ≥3.5 mg/dL)
1.54a 1.02–2.32 1.52 0.98–2.36
Hematocrit
(<30 vs. ≥30%)
0.96 0.68–1.36 0.99 0.68–1.42
Calcium x phosphate
product (<60 vs. ≥60
mg2/dL2)
0.82 0.58–1.14 0.76 0.52–1.10
Serum intact parathyroid
hormone (<200 vs.
≥200 pg/mL)
1.15 (0.82–1.61) 1.14 0.73–1.78
Adjusted for age, gender, race, education, insurance, history of smoking, presence
of diabetes mellitus, coronary artery disease, cerebrovascular disease, time on dialysis
prior to study start date, hematocrit, serum albumin, serum intact parathyroid
hormone, and serum calcium x phosphate product.
aP <0.05.
angioplasty. At 2 years, 10% of patients overall, but 13%
of patients with bypass and 5% of patients with angio-
plasty had sustained a fatal infection. For each end point,
mortality after bypass versus angioplasty was significantly
different by the log-rank test.
Table 5 summarizes the independent predictors of all-
cause death, cardiac death, and infectious death in the
Cox proportional hazards model. Among all-cause death,
the most powerful independent predictors of death were
bypass surgery (RH = 1.37 with 95% CI 1.10 to 1.70),
age (per 10-year increase in age, RH = 1.35 with 95%
CI 1.24 to 1.48), coronary artery disease (RH = 1.23
with 95% CI 1.00 to 1.52), and serum albumin less than
3.5 mg/dL (RH = 1.41 with 95% CI 1.10 to 1.80). Black
patients had a 29% survival advantage compared to white
patients (RH = 0.71 with 95% CI 0.57 to 0.87). Bypass
surgery was a strong independent risk factor for cardiac
death (RH = 1.50 with 95% CI 1.08 to 2.09). This as-
sociation, however, was not uniform over the follow-up
period (P = 0.01). The RH was 1.02 (95% CI 0.71 to 1.47;
P = 0.70) during the first 9 months, and was 6.98 (95%
CI 2.47 to 19.71; P < 0.001) after the first 9 months. In-
creasing age and presence of coronary artery disease also
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Fig. 1. Mortality of patients after undergoing initial peripheral vascu-
lar disease procedure (PVD) by surgical bypass or percutaneous trans-
luminal angioplasty. (A) All-cause cumulative mortality. (B) Cardiac
cumulative mortality. (C) Infectious cumulative mortality.
independently contributed to 31% and 38% increased
risk of cardiac death, RH = 1.31 per 10 years with 95%
CI 1.14 to 1.49 and RH = 1.38 with 95% CI 1.00 to 1.90, re-
spectively. Compared with white patients, black patients
had a relative hazard of cardiac death of 0.67 (95% CI
0.49 to 0.92).
Among infectious death, the risk of death following
bypass surgery was more than two times the risk of death
following angioplasty (RH = 2.17 with 95% CI 1.10 to
4.29). Furthermore, the risk of infectious death was sig-
nificantly increased with age (per 10-year increase in age,
RH = 1.30 with 95% CI 1.02 to 1.66), with a history of
prior transplantation (RH = 3.79 with 95% CI 1.21 to
11.87), and a serum hematocrit lower than 30% (RH =
2.01 with 95% CI 1.13 to 3.57). A calcium x phosphate
product less than 60 was associated with a 45% lower risk
of infectious death compared to patients with a higher cal-
cium x phosphate product (RH = 0.55 with 95% CI 0.31
to 0.97).
DISCUSSION
Lower extremity amputation remains a significant
threat for hemodialysis patients with PVD even after
revascularization. In our study, we found an overall
lower extremity amputation rate of 16.9 per 100 patient-
years. This rate was 22.6 per 100 patient-years follow-
ing revascularization by surgical bypass and 5.7 per 100
patient-years following revascularization by angioplasty.
Although our results are consistent with the overall am-
putation rate of 22% following surgical revascularization
reported by Donayre [10] in his review of the surgical lit-
erature in 1996, the lower incidence rate of amputation
found in patients following angioplasty should be inter-
preted with caution. Patients undergoing angioplasty may
not be strictly comparable to those undergoing surgical
bypass. It is possible that the patients who were man-
aged with angioplasty had less severe symptoms or less se-
vere disease on angiography compared to those managed
with vascular bypass surgery [15]. On the other hand,
surgical bypass may be associated with more prolonged
hospitalization and immobility, and perhaps greater nu-
tritional complications that would predispose patients to
impaired postoperative wound healing and further is-
chemic and/or infectious complications (i.e., heel or sacral
pressure necrosis with decubitus ulcer formation) leading
to subsequent amputation. A randomized clinical trial
would be the best design to assess risk of amputation
with bypass versus angioplasty since in nonrandomized
studies, an observed association between exposure (by-
pass or angioplasty) and outcome (lower extremity am-
putation) could be due not necessarily to the exposure
but rather to factors (such as disease severity) associ-
ated with the disease process that led patients to the
exposure.
Male hemodialysis patients had greater risk of lower
extremity amputation following revascularization for
PVD than female patients. Eggers, Gohdes, and Pugh [3]
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Table 5. Relative hazard of all-cause, cardiac and infectious death among 800 hemodialysis patients undergoing lower extremity revascularization
(all procedures)
All-cause mortality Cardiac mortality Infectious mortality
Adjusted relative Adjusted relative Adjusted relative
Characteristics hazard (95% CI) hazard (95% CI) hazard (95% CI)
Bypass vs. angioplasty 1.37a (1.10–1.70) 1.50a (1.08–2.09) 2.17a (1.10–4.29)
Age (per 10 years) 1.35a (1.24–1.48) 1.31a (1.14–1.49) 1.30a (1.02–1.66)
Gender: male vs. female 1.12 (0.92–1.35) 1.11 (0.83–1.47) 1.45 (0.84–2.52)
Race: black vs. white 0.71a (0.57–0.87) 0.67a (0.49–0.92) 1.15 (0.66–2.00)
High school graduate vs. no high school diploma 0.94 (0.76–1.16) 0.94 (0.68–1.30) 0.82 (0.44–1.53)
No insurance or Medicaid vs. private or Medicare 1.26 (0.96–1.65) 1.07 (0.70–1.64) 1.58 (0.79–3.13)
History of smoking vs. none 1.05 (0.86–1.28) 0.89 (0.66–1.20) 1.29 (0.74–2.23)
Coronary artery disease vs. none 1.23a (1.00–1.52) 1.38a (1.00–1.90) 1.13 (0.63–2.04)
Diabetes mellitus vs. none 1.15 (0.94–1.41) 1.14 (0.84–1.54) 1.37 (0.77–2.43)
Prior transplantation vs. none 1.39 (0.80–2.41) 1.10 (0.45–2.73) 3.79a (1.21–11.87)
Time on dialysis (per year) 1.03 (0.99–1.07) 1.00 (0.95–1.07) 1.01 (0.91–1.12)
Serum albumin (<3.5 vs. ≥3.5 mg/dL) 1.41a (1.10–1.80) 1.33 (0.93–1.91) 1.49 (0.74–3.01)
Hematocrit (<30 vs. ≥30%) 1.13 (0.93–1.38) 0.94 (0.70–1.27) 2.01a (1.13–3.57)
Calcium x phosphate product (<60 vs. ≥60 mg2/dL2) 0.88 (0.71–1.08) 0.91 (0.67–1.23) 0.55a (0.31–0.97)
Serum intact parathyroid hormone (<200 vs. ≥200
pg/mL)
1.06 (0.83–1.35) 0.84 (0.59–1.19) 1.24 (0.60–2.58)
Adjusted for age, gender, race, education, insurance, history of smoking, presence of diabetes mellitus, coronary artery disease, cerebrovascular disease, time on
dialysis prior to study start date, hematocrit, serum albumin, serum intact parathyroid hormone, and serum calcium x phosphate product.
aP < 0.05.
also reported that male patients with ESRD were 23%
more likely to have a lower extremity amputation than
were female patients. The reason for this increased risk in
male patients remains unclear but male patients without
ESRD have been reported to receive more aggressive
care for PVD [16].
In our study, we found that black patients on hemodial-
ysis were significantly less likely to undergo revascular-
ization by bypass compared to whites and were then
less likely than their white counterparts to have a revi-
sion of their revascularization. Furthermore, we found
that black patients on hemodialysis had an increased risk
of lower extremity amputation following revasculariza-
tion for PVD, even after adjusting for socioeconomic
status and comorbid conditions. These observations par-
allel ones made in the general population of patients with
PVD where black patients were more likely than whites
to undergo lower extremity amputation for severe PVD
[17–19]. There are several possible explanations for these
observed racial disparities, including variations in disease
distribution and severity, delay in presentation, distrust in
the medical system, nonadherence to treatment recom-
mendations, and differential access to care particularly in
the pre-ESRD period. Similarly, the rate of lower extrem-
ity amputation following revascularization was also much
higher among patients with Medicaid or no insurance at
start of hemodialysis. Poor access to care in the pre-ESRD
period may be associated with delay in diagnosis leading
to more severe distal disease at the time of revasculariza-
tion with subsequent worse outcome [20, 21]. Other stud-
ies have shown that patients who are poor, uninsured, or
without a regular source of care may face impediments
to access, as evidenced by lower use of health services
[20, 21].
Diabetes mellitus is an important known risk factor
for PVD. The Framingham Study was one of the first
epidemiologic studies to ascertain diabetes mellitus as
a risk factor for intermittent claudication with an annual
age-adjusted incidence of 12.6 per 1000 diabetic men and
8.4 per 1000 diabetic women compared to 3.3 and 1.3
per 1000 nondiabetic men and women, respectively [22].
Calle-Pascual et al [23] compared the outcome of periph-
eral vascular reconstruction in the general population
of diabetic and nondiabetic patients. In their study, di-
abetic patients had more frequent distal reconstruction,
and a lower cumulative limb salvage rate than nondi-
abetic patients for the same level of bypass [23]. Simi-
larly in our study, diabetic patients on hemodialysis had
a much higher risk of lower extremity amputation fol-
lowing revascularization. This may be due to more ad-
vanced stages of ischemia, and possibly more significant
distal small vessel disease, leading to poor wound healing
of foot ulcers, and higher amputation rate. Hemodialysis
patients with coronary artery disease (CAD) were more
likely to be offered revascularization by bypass than an-
gioplasty. Furthermore the incidence of lower extremity
amputation following revascularization was much higher
in patients with CAD compared to patients without CAD.
This increased risk weakened and was not statistically
significant after adjusting for socioeconomic status and
other comorbid conditions. Nevertheless, other studies
have shown that patients with PVD are more likely to
suffer from CAD and cerebrovascular disease, which also
account for much of the mortality after lower extremity
revascularization [24].
Our data indicate that mortality of hemodialysis pa-
tients following revascularization by surgical bypass was
higher compared to angioplasty for all-cause, cardiac, and
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infectious causes of death. In their comprehensive re-
view of the literature, O’Hare and Johansen [25] reported
a 30-day mortality of 9.48% and a 2-year mortality of
51.4% following revascularization by bypass; this is lower
than our estimated 30-day mortality of 12.6% and 2-year
mortality of 63% for all-cause of death among patients
who underwent revascularization by bypass. Unlike our
study population, which encompasses the experience of
only hemodialysis patients in the United States, O’Hare
and Johansen reported the weighted mean 2-year sur-
vival of 15 surgical series, involving a total of 358 patients
treated with different methods, including hemodialysis,
peritoneal dialysis, and transplantation. In agreement
with our results, Johnson et al [6] reported the outcome
of surgical revascularization in one of the largest surgical
series, with 53 patients (70% on hemodialysis, 11% on
peritoneal dialysis, and 19% kidney transplant patients).
The overall 1- and 2-year patients mortality were 42%
and 62%, respectively [6]. By and large, ESRD patients
experience a much greater risk of death following revas-
cularization by bypass since the 30-day mortality and the
2-year mortality in the non-ESRD population are much
lower and have been reported at 3.1% and 24.1%, re-
spectively [25].
As reported in the surgical literature, 40% to 60% of
deaths during the postoperative period occurred as a re-
sult of cardiovascular events [10]. A systematic cardiac
evaluation before PVD revascularization should remain
an important preoperative measure, particularly in pa-
tients undergoing bypass procedures, older patients, and
patients with a history of CAD, diabetes mellitus, and
low serum albumin. Infections usually account for most
of the remaining mortality observed postoperatively.
Harrington et al [26], in their series of 39 ESRD patients
with surgical revascularization, reported up to 43% of
death related to sepsis. In our study, patients undergoing
bypass procedures were at increased risk of infection re-
lated mortality but so were also older patients, patients
with a prior history of transplantation, and patients with a
low hematocrit. This risk was lower for patients with a cal-
cium x phosphate product below 60 mg2/dL2. Although
we believe that a state of immunosupression might have
played a role in patients with a history of prior trans-
plantation, we had no information on current use of
immunosupressant drugs while on hemodialysis. The as-
sociation of a low hematocrit (<30%) with infectious
death has been previously reported [2]. However, the spe-
cific nature of the relationship between hematocrit and
infectious death has yet to be established. Finally, an ele-
vated calcium x phosphate product above 60 mg2/dL2 ap-
pears to be an important factor leading to increased risk
of vascular calcification [27]. It is possible that patients
with higher calcium x phosphate product have more se-
vere PVD responsible for tissue loss and increasing their
risk for infectious death. In support of the association
of PVD with infection, we analyzed the USRDS-Case-
Mix Severity Study with more than 4000 hemodialysis pa-
tients, and identified PVD as an independent risk factor
for septicemia among diabetic patients; RR (95% CI) =
1.4 (1.1 to 1.9) [28].
There are no controlled studies of the use of angio-
plasty compared to surgical bypass in the ESRD popu-
lation. However, a multicenter prospective randomized
study comparing percutaneous transluminal angioplasty
with bypass surgery for lower extremity ischemia in the
general population, the Veterans Affairs Cooperative
Study 199, revealed considerably higher 5-year morbidity
and mortality rates in patients undergoing surgical revas-
cularization. In surgically treated patients, mortality was
13.1% per year, whereas it was 8.4% per year for patients
treated with angioplasty [29].
There are several limitations associated with the data
sources used to conduct this study and the interpreta-
tion of the results. Because data in our analysis were
abstracted from a single chart review, there was no oppor-
tunity to track individual changes in albumin, hematocrit,
intact PTH, or calcium x phosphate product over time.
Insurance status is another variable that changes over
time, as almost all patients with ESRD become eligible for
Medicare. Some additional features of the data sources
merit further comment. We had no information on sever-
ity of PVD (for example, based on symptoms, physical
examination, or an arteriogram), type of graft used for
surgical revascularization, and indication for or lateral-
ity of the operative procedure. Also patients undergoing
angioplasty may not be strictly comparable to those pa-
tients undergoing surgical revascularization. We also rec-
ognize the limitations associated with the use of prevalent
hemodialysis patients in assessing survival comparisons
following revascularization procedures as individual pa-
tients may be at different time points in the course of
their illness. Furthermore, it is possible that patients may
have had revascularization procedures soon after starting
hemodialysis and did not survive to be included in this
prevalent cohort. This may in fact underestimate the true
rates of amputation or death following revascularization.
We recognize that cause-specific deaths using the Health
Care Financing Administration (HCFA) ESRD death
notification form have limitations. Rocco et al [30] com-
pared causes of death obtained using the HCFA ESRD
death notification classification systems with those using
death ascertainment from the HEMO Study and found
that sensitivity of most HCFA causes of death was fair
while the specificity was extremely high (∼95%). As with
all retrospective studies, causal inferences must be made
with caution [31]. In this regard, future prospective stud-
ies of risk factors for lower extremity amputation fol-
lowing revascularization in incident ESRD patients are
needed as well as controlled studies of the use of angio-
plasty to treat PVD in this high risk population.
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CONCLUSION
The present study provides a more representative pic-
ture of lower extremity revascularization outcomes in
hemodialysis patients, as it encompasses the experience
of hemodialysis patients in the United States, rather than
a single institution. The results of this study have several
important implications since there are very few data on
the incidence and predictors of lower extremity amputa-
tion and patients survival following revascularization in a
large representative cohort of hemodialysis patients. Be-
cause results after revascularization are discouragingly
poor among patients with ESRD and because there is
considerable patient morbidity and mortality related to
failed revascularization procedures, attention probably
should be focused on more aggressive screening of PVD
in hemodialysis patients. Furthermore, identification of
modifiable risk factors, patient education, and optimal
care of ischemic lower extremities should be emphasized
at an early stage of the disease process.
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